Comparison between Measles-Rubella (MR) Vaccine and Purified Protein Derivative (PPD) injection in warts treatment.
Not Applicable
Completed
- Conditions
- Health Condition 1: B079- Viral wart, unspecified
- Registration Number
- CTRI/2021/06/034219
- Lead Sponsor
- Dr Manish Kumar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
a. Patients with recalcitrant or recurrent or multiple or resistant to treat cutaneous warts.
b. Patients, where first and second line of treatment have produced no effect.
c. Patient of both sexes aged more than 12 years and less than 70 years.
d. No concurrent treatment for cutaneous wart
Exclusion Criteria
a. Patients with fever or signs of any inflammation or infection
b. Patient of both sexes aged less than 12 years and more than70 years
c. Pregnancy or planning to conceive.
d. Lactation
e. Immunosuppression or immunosuppressive disease.
f. Ano-genital/ Facial warts.
g. Past history of asthma, allergic skin disorders, meningitis, convulsions, hypersensitivity to any antigens.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The response will be evaluated as: <br/ ><br>a.Complete clearance- if there is disappearance of the cutaneous wart and appearance of normal skin <br/ ><br>b.Partial response - if there is more than 50% reduction in size. <br/ ><br>c.Minimal response - if the reduction in size is less than 50%. <br/ ><br>d.No response <br/ ><br> <br/ ><br>Timepoint: The response (outcome) will be assessed at a gap of 2-weeks interval until complete clearance or for a maximum of 5 treatments.Follow up of patients will be done for 3 months for clinical assessment of results and to see and check for any recurrence. <br/ ><br>
- Secondary Outcome Measures
Name Time Method 1.Resolution of distant untreated warts will also assessed. <br/ ><br>2.safety and adverse effects of intralesional Measles-Rubella (MR) vaccine and Purified Protein Derivative (PPD) in treatment of cutaneous warts will be assessedTimepoint: The response (outcome) will be assessed at a gap of 2-weeks interval until complete clearance or for a maximum of 5 treatments.Follow up of patients will be done for 3 months for clinical assessment of results and to see and check for any recurrence. <br/ ><br>